Sugi Predict

Sugi Predict / Compounds / Clostebol

Clostebol

Clostebol

SCHEMBL146712

C[C@]12CC[C@H]3[C@@H](CCC4=C(Cl)C(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 6/20 0.76
▸ SRD5A2 P31213 2/20 0.65
▸ CYP19A1 P11511 7/20 0.58
▸ CYP3A4 P08684 4/20 0.58
▸ AR P10275 4/20 0.58
▸ LMNA P02545 3/20 0.58
▸ HSD17B10 Q99714 3/20 0.58
▸ TSHR P16473 3/20 0.58
▸ NR3C1 P04150 2/20 0.58
▸ PGR P06401 2/20 0.58
▸ SERPINA6 P08185 2/20 0.58
▸ SNCA P37840 2/20 0.58
▸ CACNA1C Q13936 2/20 0.58
▸ CYP51A1 Q16850 2/20 0.58
▸ GPBAR1 Q8TDU6 2/20 0.58
▸ SIGMAR1 Q99720 2/20 0.58
▸ MAPT P10636 1/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ OR51E2 Q9H255 1/20 0.58
▸ ESR1 P03372 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clostebol SCHEMBL4437252 1.00 SHBG (0.76) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL216172 0.95 SHBG (0.69) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL23458227 0.92 SHBG (0.65) SHBGSRD5A2CYP19A1CYP3A4AR
Clostebol SCHEMBL23458372 0.88 SHBG (0.60) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL2545773 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL21850133 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL1682762 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL22100655 0.87 SHBG (0.79) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL2733387 0.86 SHBG (1.00) SHBGSRD5A2CYP19A1CYP3A4AR
SCHEMBL10274070 0.86 SHBG (1.00) SHBGSRD5A2CYP19A1CYP3A4AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3612223-B1 TREATING MALE SENESCENCE NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2024-07-31 — — EP claimed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US claimed
EP-3612223-A1 Treating Male Senescence National Institute Of Biological Sciences, Beijing (CN) 2020-02-26 — — EP claimed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US claimed
WO-2018192416-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-25 — — WO claimed
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 — — US claimed
US-20160279146-A1 METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF SELECTIVE ESTROGEN-RECEPTOR MODULATOR-INDUCED ADVERSE DRUG REACTIONS LIMOXIFEN B.V. (NL) 2016-09-29 — — US claimed
EP-3068433-A1 METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF SELECTIVE ESTROGEN-RECEPTOR MODULATOR-INDUCED ADVERSE DRUG REACTIONS Limoxifen B.V. (NL) 2016-09-21 — — EP claimed
CN-104181268-B One is measured 15 kinds of androgenic methods of forbidding in cosmetics simultaneously CHINESE ACADEMY OF INSPECTION AND QUARANTINE (CN) 2016-05-11 — — CN claimed
WO-2015069115-A1 METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF SELECTIVE ESTROGEN-RECEPTOR MODULATOR-INDUCED ADVERSE DRUG REACTIONS LIMBIC BRAIN COMPANY B.V. (NL) 2015-05-14 — — WO claimed
US-20030114430-A1 Stabilized injectable suspension of a steroidal drug PHARMACIA CORPORATION 2003-06-19 — — US claimed
WO-2002102390-A1 ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS NOVEN PHARMACEUTICALS, INC. (US) 2002-12-27 — — WO claimed
US-20020054910-A1 Topical composition for covering a skin lesion MONTERESEARCH S.R.L. (IT) 2002-05-09 — — US claimed
WO-2002006826-B1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT E SCRIP INC (US) 2002-04-04 — — WO claimed
US-20020032581-A1 Single-patient drug trials used with accumulated database: risk of habituation OPT-E-SCRIP, INC. 2002-03-14 — — US claimed
EP-1179352-A1 Topical composition for covering a skin lesion MONTERESEARCH S.r.l. (IT) 2002-02-13 — — EP claimed
WO-2002006826-A1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT-E-SCRIP, INC. (US) 2002-01-24 — — WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
EP-0496520-A1 Novel bone acting agents MERCK & CO. INC. (US) 1992-07-29 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL SHBG 293/4885SRD5A2 1768/4885CYP19A1 669/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL SHBG 293/4885SRD5A2 1768/4885CYP19A1 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.